Welcome to our dedicated page for ATRECA A news (Ticker: BCEL), a resource for investors and traders seeking the latest updates and insights on ATRECA A stock.
Atreca Inc (NASDAQ: BCEL) is a pioneering biotechnology company dedicated to the development of innovative cancer immunotherapeutics. Leveraging its unique Immune Repertoire Capture™ (IRC™) technology, Atreca has gained unparalleled insight into the human immune response. This advanced platform allows the company to identify unique antibody-target pairs generated by the immune system during an active immune response against tumors.
Atreca's core focus is on developing antibody-drug conjugates (ADCs), a promising class of therapeutics that combines the targeting capabilities of antibodies with potent anti-cancer drugs. The company’s lead program, APN-497444, targets a novel tumor glycan and exemplifies the potential of Atreca’s discovery platform to generate first-in-class oncology treatments.
Recently, Atreca has undergone a significant corporate reorganization aimed at reducing expenses and extending its cash runway. This includes suspending the development of ATRC-101, a promising therapeutic previously advanced into the clinic, and reducing its workforce by approximately 40%. The company is now concentrating its efforts on advancing preclinical ADC candidates, particularly APN-497444, while preserving its core discovery capabilities.
Atreca has also established strategic partnerships to further its mission. Notably, it has licensed MAM01/ATRC-501, a clinical candidate for malaria prevention, to the Bill & Melinda Gates Medical Research Institute. This partnership underscores Atreca’s commitment to leveraging its platform for both oncology and infectious diseases.
The company’s financial condition and strategic decisions, such as the termination of a long-term lease agreement to reduce operating expenses, reflect a careful balance of innovation and fiscal responsibility. Atreca’s leadership, including CEO John Orwin, emphasizes the importance of focusing resources on high-potential projects while exploring strategic alternatives for non-core assets.
For those interested in contributing to Atreca’s groundbreaking work, the company is actively seeking talented individuals. Open positions can be found on their careers page.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), announced it will present data from the Phase 1b study of ATRC-101 at the American Society of Clinical Oncology 2023 Annual Meeting from June 2-6 in Chicago. The presentation, titled "Interim update of the ATRC-101 phase 1b trial in advanced solid tumors", will take place on June 4, 2023, from 9:45 AM to 12:45 PM CDT. This trial aims to evaluate ATRC-101's effectiveness in treating multiple solid tumors, expanding Atreca's innovative antibody-based therapeutic portfolio that targets unique tumor antigens derived from the human immune response. The company is actively enrolling patients for this trial, highlighting its commitment to advancing cancer therapies.
Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology company, announced that CEO John A. Orwin will participate in a panel discussion on T-Cells and "Informative B-Cells" at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, from 10:00 to 10:45 AM ET. The panel aims to address innovative approaches in oncology. A live webcast will be available for registered attendees, who can also schedule one-on-one meetings with Atreca's management. The company's unique discovery platform focuses on developing novel therapeutics based on the human immune response, leading to candidates like ATRC-101, currently in a Phase 1b study for solid tumor cancers. For more details, visit Atreca's website.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), published its fourth quarter and full-year 2022 results, revealing a net loss of $97.2 million, translating to a net loss per share of $2.52. The ongoing Phase 1b trial for ATRC-101 shows promising results, with 59% disease control in patients with high target expression. The company expects go/no-go decisions for Phase 2 trials by year-end. Additionally, Atreca is advancing preclinical programs APN-497444 and APN-346958, with clinical candidate nominations anticipated in 2023. Financially, cash and equivalents stood at $70.5 million, with R&D expenses totaling $66.8 million for the year.
FAQ
What is the current stock price of ATRECA A (BCEL)?
What is the market cap of ATRECA A (BCEL)?
What is Atreca Inc's primary focus?
What technology does Atreca use for its research?
What is APN-497444?
Why did Atreca suspend the development of ATRC-101?
What partnerships has Atreca established?
What recent corporate actions has Atreca taken?
Who is the CEO of Atreca?
How does Atreca's discovery platform benefit oncology research?
What opportunities are there to work at Atreca?
Where can I find the latest financial results of Atreca?
